Neuroendocrine Tumours

• Data-driven miRNA classifier as response predictor for immune checkpoint inhibitor treatment in advanced-stage cancer patients
• Preoperative neutrophil‐to‐lymphocyte ratio (NLR) predicts recurrence after surgery in patient with pancreatic neuroendocrine neoplasm (PanNEN)
• Clinical outcome of personalised treatment guided by genome and transcriptome sequencing in patients with neuroendocrine neoplasms: Updated results...
• Tumour cells mirror embryonic developmental programs to acquire invasive and metastatic capabilities
• Participant Clinical Case Discussion: Metastatic prostate cancer with neuroendocrine differentiation
• The genomic landscape
• Challenges in pathological and molecular classifications
• Seeking the optimal treatment sequence in advanced disease
• SUNitinib with EVOfosfamide (TH-302) for G1/G2 metastatic pancreatic neuroendocrine tumours (pNETs) naïve for systemic treatment. The SUNEVO phase...
• Poster Discussion – NETs and endocrine tumours - Invited Discussant 1382PD, 1383PD and 1834PD
• Poster Discussion – NETs and endocrine tumours - Invited Discussant 1385PD and 1386PD
• Proffered Paper – NETs and endocrine tumours - Invited Discussant LBA76, LBA93 and 1380O
• Proffered Paper – NETs and endocrine tumours - Invited Discussant 1381O and 512O
• Efficacy and safety of surufatinib in patients with well-differentiated advanced extrapancreatic neuroendocrine tumors (NETs): results from the ran...
• 177Lu-DOTATATE plus 166Ho-radioembolization in patients with neuroendocrine tumours; a single center, prospective, interventional, non-comparative,...
• Malignant Non-adrenal Paraganglioma (mPara) and Adrenal Pheochromocytoma (mPheo) a Comparative Comprehensive Genomic Profiling (CGP) Study
• RNA expression profiles and splicing alterations in grade 1/2 neuroendocrine neoplasms from small intestine origin (siNENs). Final results of the G...
• Proportion of Peripheral Lymphocyte Subsets Correlates with the Progression-free Survival and Metastatic Status of Pancreatic Neuroendocrine Tumor...
• Baseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120 mg every 14 days in patients with progressive pancreatic or m...
• Diabetes Is Associated With Pancreatic Neuroendocrine Tumors Growth and Metastasis
• Treatment with somatostatin analogues after radiopeptide therapy
• Safety and Tolerability of Surufatinib in Western Patients with Solid Tumors
• The impact of tumour absorbed dosimetry with survival outcomes after peptide receptor radionuclide therapy in metastatic neuroendocrine tumours.
• Opportunist and Serious Infections in Patients with Neuroendocrine Tumors Treated With Everolimus: A Multicenter Study of Real World Patients
• Neutrophil-lymphocyte ratio as an independent predictive factor in Neuroendocrine Neoplasms

• « Previous
• 1
• 2
• ...
• 16
• Next »